Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of...

Descripción completa

Detalles Bibliográficos
Autores principales: Teague, Taylor T., Payne, Stephanie R., Kelly, Bryan T., Dempsey, Timothy M., McCoy, Rozalina G., Sangaralingham, Lindsey R., Limper, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004115/
https://www.ncbi.nlm.nih.gov/pubmed/35410255
http://dx.doi.org/10.1186/s12931-022-02001-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004115/
https://www.ncbi.nlm.nih.gov/pubmed/35410255
http://dx.doi.org/10.1186/s12931-022-02001-0

Ejemplares similares